Regeneron’s Antibody Therapy A Lifesaver In Seronegative COVID-19 Patients
Another Landmark For RECOVERY Trial
Identifying patients who have not mounted an immune response to SARS-CoV2 and treating them with the antibody cocktail cuts risk of death by a fifth.
You may also be interested in...
Comirnaty and Spikevax to get EU label update on cardiac safety, Japanese filing for REGEN-COV, plus vaccine progress for ReiThera and Genexine.
Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.
AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.